{"id":19056,"date":"2024-12-20T15:26:51","date_gmt":"2024-12-20T07:26:51","guid":{"rendered":"https:\/\/flcube.com\/?p=19056"},"modified":"2024-12-20T15:26:56","modified_gmt":"2024-12-20T07:26:56","slug":"hob-biotech-group-corp-acquired-by-sino-biopharmaceutical-ltd-for-ivd-synergies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19056","title":{"rendered":"HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies"},"content":{"rendered":"\n

China-based in vitro diagnostic (IVD) reagents specialist HOB Biotech Group Corp., Ltd (SHA: 688656<\/a>) has announced receiving a tender offer from its compatriot firm Sino Biopharmaceutical Ltd.’s (HKG: 1177<\/a>) controlling firm. This strategic move will see a capital infusion of RMB 525 million (USD 72 million), equating to a 55% stake in H OB, positioning it to become Sino Bio\u2019s first unit listed in the domestic market.<\/p>\n\n\n\n

Strategic Synergy Between IVD and Pharmaceutical Sectors<\/strong>
The acquisition is expected to deliver synergistic effects between HOB’s IVD business and Sino Bio\u2019s pharmaceutical efforts. By combining the expertise in IVD reagents with Sino Bio\u2019s pharmaceutical development, the collaboration aims to create a more comprehensive approach to healthcare solutions, potentially leading to innovations in diagnostic and therapeutic interventions.<\/p>\n\n\n\n

Implications for the Healthcare Sector and Market Expansion<\/strong>
This acquisition not only strengthens the position of both companies within the Chinese market but also signals a significant step towards market expansion and the integration of IVD and pharmaceutical sectors. The combined efforts are anticipated to contribute positively to the healthcare sector by enhancing the range and quality of services and products available to patients.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based in vitro diagnostic (IVD) reagents specialist HOB Biotech Group Corp., Ltd (SHA: 688656) has…<\/p>\n","protected":false},"author":1,"featured_media":19058,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[908,541,1270,313],"class_list":["post-19056","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-1177","tag-hob-biotech","tag-sha-688656","tag-sino-biopharmaceutical"],"yoast_head":"\nHOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based in vitro diagnostic (IVD) reagents specialist HOB Biotech Group Corp., Ltd (SHA: 688656) has announced receiving a tender offer from its compatriot firm Sino Biopharmaceutical Ltd.'s (HKG: 1177) controlling firm. This strategic move will see a capital infusion of RMB 525 million (USD 72 million), equating to a 55% stake in H OB, positioning it to become Sino Bio\u2019s first unit listed in the domestic market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19056\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies\" \/>\n<meta property=\"og:description\" content=\"China-based in vitro diagnostic (IVD) reagents specialist HOB Biotech Group Corp., Ltd (SHA: 688656) has announced receiving a tender offer from its compatriot firm Sino Biopharmaceutical Ltd.'s (HKG: 1177) controlling firm. This strategic move will see a capital infusion of RMB 525 million (USD 72 million), equating to a 55% stake in H OB, positioning it to become Sino Bio\u2019s first unit listed in the domestic market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19056\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-20T07:26:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-20T07:26:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2009.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19056#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19056\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies\",\"datePublished\":\"2024-12-20T07:26:51+00:00\",\"dateModified\":\"2024-12-20T07:26:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19056\"},\"wordCount\":204,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19056#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2009.png\",\"keywords\":[\"HKG: 1177\",\"HOB Biotech\",\"SHA: 688656\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19056#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19056\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19056\",\"name\":\"HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19056#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19056#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2009.png\",\"datePublished\":\"2024-12-20T07:26:51+00:00\",\"dateModified\":\"2024-12-20T07:26:56+00:00\",\"description\":\"China-based in vitro diagnostic (IVD) reagents specialist HOB Biotech Group Corp., Ltd (SHA: 688656) has announced receiving a tender offer from its compatriot firm Sino Biopharmaceutical Ltd.'s (HKG: 1177) controlling firm. This strategic move will see a capital infusion of RMB 525 million (USD 72 million), equating to a 55% stake in H OB, positioning it to become Sino Bio\u2019s first unit listed in the domestic market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19056#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19056\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19056#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2009.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/2009.png\",\"width\":1080,\"height\":720,\"caption\":\"HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19056#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies - Insight, China's Pharmaceutical Industry","description":"China-based in vitro diagnostic (IVD) reagents specialist HOB Biotech Group Corp., Ltd (SHA: 688656) has announced receiving a tender offer from its compatriot firm Sino Biopharmaceutical Ltd.'s (HKG: 1177) controlling firm. This strategic move will see a capital infusion of RMB 525 million (USD 72 million), equating to a 55% stake in H OB, positioning it to become Sino Bio\u2019s first unit listed in the domestic market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19056","og_locale":"en_US","og_type":"article","og_title":"HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies","og_description":"China-based in vitro diagnostic (IVD) reagents specialist HOB Biotech Group Corp., Ltd (SHA: 688656) has announced receiving a tender offer from its compatriot firm Sino Biopharmaceutical Ltd.'s (HKG: 1177) controlling firm. This strategic move will see a capital infusion of RMB 525 million (USD 72 million), equating to a 55% stake in H OB, positioning it to become Sino Bio\u2019s first unit listed in the domestic market.","og_url":"https:\/\/flcube.com\/?p=19056","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-20T07:26:51+00:00","article_modified_time":"2024-12-20T07:26:56+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2009.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19056#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19056"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies","datePublished":"2024-12-20T07:26:51+00:00","dateModified":"2024-12-20T07:26:56+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19056"},"wordCount":204,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=19056#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2009.png","keywords":["HKG: 1177","HOB Biotech","SHA: 688656","Sino Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19056#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19056","url":"https:\/\/flcube.com\/?p=19056","name":"HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=19056#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=19056#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2009.png","datePublished":"2024-12-20T07:26:51+00:00","dateModified":"2024-12-20T07:26:56+00:00","description":"China-based in vitro diagnostic (IVD) reagents specialist HOB Biotech Group Corp., Ltd (SHA: 688656) has announced receiving a tender offer from its compatriot firm Sino Biopharmaceutical Ltd.'s (HKG: 1177) controlling firm. This strategic move will see a capital infusion of RMB 525 million (USD 72 million), equating to a 55% stake in H OB, positioning it to become Sino Bio\u2019s first unit listed in the domestic market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19056#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19056"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=19056#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2009.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2009.png","width":1080,"height":720,"caption":"HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19056#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HOB Biotech Group Corp. Acquired by Sino Biopharmaceutical Ltd for IVD Synergies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/2009.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19056","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19056"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19056\/revisions"}],"predecessor-version":[{"id":19059,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19056\/revisions\/19059"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/19058"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19056"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19056"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19056"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}